Edwards Lifesciences (EW) Gross Profit (2009 - 2026)

Edwards Lifesciences' Gross Profit history runs 18 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• On a quarterly basis, Gross Profit rose 15.74% year-over-year to $1.3 billion in Q1 2026; TTM through Mar 2026 was $4.9 billion, a 11.8% increase from a year earlier, with the FY2025 full-year figure at $4.7 billion, up 9.52% from the prior year.
• Gross Profit climbed to $1.3 billion in Q1 2026 per EW's latest filing, from $1.2 billion in the prior quarter.
• Across five years, Gross Profit topped out at $1.3 billion in Q1 2026 and bottomed at $528.7 million in Q4 2022.
• The 5-year median for Gross Profit is $1.1 billion (2024), against an average of $1.1 billion.
• Across the five-year window, Gross Profit slumped 48.18% in 2022 and surged 92.06% in 2023, its largest moves.
• Year by year, Gross Profit stood at $528.7 million in 2022, then surged by 92.06% to $1.0 billion in 2023, then increased by 7.7% to $1.1 billion in 2024, then climbed by 12.16% to $1.2 billion in 2025, then grew by 4.84% to $1.3 billion in 2026.
• Per Business Quant, the three latest EW Gross Profit figures stand at $1.3 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.2 billion (Q3 2025).